GBA1 and Parkinson disease: Clinical trials are currently evaluating the efficacy of oral ambroxol in type 1 GD, PD dementia and GBA1-PD (ClinicalTrials.gov Identifier: NCT03950050, NCT02914366 and NCT02941822, respectively).